Charles River Laboratories International, Inc.
CRL
$178.14
-$0.80-0.45%
NYSE
| 09/27/2025 | 06/28/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -2.64% | 4.87% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.64% | 4.87% | |||
| Cost of Revenue | 0.64% | 0.70% | |||
| Gross Profit | -8.19% | 12.77% | |||
| SG&A Expenses | -6.55% | 5.39% | |||
| Depreciation & Amortization | -22.11% | -13.71% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.60% | 1.17% | |||
| Operating Income | -7.88% | 28.37% | |||
| Income Before Tax | 22.10% | 98.50% | |||
| Income Tax Expenses | 68.99% | 85.40% | |||
| Earnings from Continuing Operations | 5.43% | 103.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -208.99% | 10.27% | |||
| Net Income | 4.01% | 105.45% | |||
| EBIT | -7.88% | 28.37% | |||
| EBITDA | -47.21% | 49.42% | |||
| EPS Basic | 3.87% | 111.82% | |||
| Normalized Basic EPS | -22.98% | 55.46% | |||
| EPS Diluted | 3.77% | 112.00% | |||
| Normalized Diluted EPS | -23.06% | 55.47% | |||
| Average Basic Shares Outstanding | 0.13% | -3.02% | |||
| Average Diluted Shares Outstanding | 0.22% | -3.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||